Inflarx (NASDAQ:IFRX) Raised to “Buy” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Inflarx (NASDAQ:IFRX) from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. Zacks Investment Research currently has $3.75 price target on the stock.

According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “

Other research analysts have also recently issued research reports about the company. Raymond James set a $44.00 target price on Inflarx and gave the company a buy rating in a research note on Friday, May 24th. ValuEngine upgraded Inflarx from a hold rating to a buy rating in a research note on Thursday, February 28th. Guggenheim started coverage on Inflarx in a research report on Friday, February 22nd. They set a buy rating and a $65.00 price objective for the company. SunTrust Banks lowered Inflarx from a buy rating to a hold rating and reduced their price objective for the company from $55.00 to $5.00 in a research report on Wednesday, June 5th. Finally, Svb Leerink lowered Inflarx from an outperform rating to a market perform rating in a research report on Wednesday, June 5th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. Inflarx presently has an average rating of Hold and an average target price of $15.72.

IFRX opened at $3.28 on Wednesday. The company has a market capitalization of $79.97 million and a PE ratio of -2.34. Inflarx has a 52 week low of $2.91 and a 52 week high of $53.10.

Inflarx (NASDAQ:IFRX) last released its earnings results on Thursday, March 28th. The company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.02). As a group, analysts expect that Inflarx will post -2.08 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp bought a new position in Inflarx during the 3rd quarter valued at approximately $277,000. Spark Investment Management LLC bought a new stake in shares of Inflarx in the 1st quarter worth $359,000. Millennium Management LLC increased its holdings in shares of Inflarx by 18.1% in the 4th quarter. Millennium Management LLC now owns 72,153 shares of the company’s stock worth $2,624,000 after purchasing an additional 11,080 shares in the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of Inflarx by 36.1% in the 1st quarter. Artisan Partners Limited Partnership now owns 52,197 shares of the company’s stock worth $1,973,000 after purchasing an additional 13,834 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in shares of Inflarx in the 4th quarter worth $526,000. 55.89% of the stock is owned by institutional investors.

About Inflarx

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Featured Article: Put Option

Get a free copy of the Zacks research report on Inflarx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Leoni  PT Set at €14.00 by Warburg Research
Leoni PT Set at €14.00 by Warburg Research
ADO Properties  PT Set at €50.00 by UBS Group
ADO Properties PT Set at €50.00 by UBS Group
Soliton Inc’s  Lock-Up Period To Expire Tomorrow
Soliton Inc’s Lock-Up Period To Expire Tomorrow
Nicholas Devlin Sells 6,004 Shares of Majestic Wine PLC  Stock
Nicholas Devlin Sells 6,004 Shares of Majestic Wine PLC Stock
Short Interest in Xeris Pharmaceuticals Inc  Decreases By 5.1%
Short Interest in Xeris Pharmaceuticals Inc Decreases By 5.1%
Zacks Investment Research Downgrades Genmab A/S  to Hold
Zacks Investment Research Downgrades Genmab A/S to Hold


 
© 2006-2019 Zolmax.